title: Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.
abstract: Evidence is continuing to accumulate that the FMS-like tyrosine kinase 3 (FLT3) receptor plays an important role in acute leukemias. Acute myeloid leukemia patients often express constitutive active mutant forms of the receptor in their leukemic cells. A t(12;13)(p13;q12) translocation between Tel and the FLT3 receptor was recently described in a patient with myeloproliferative disease (MPD). Here a Tel-FLT3 construct mimicking this fusion protein was used to generate transgenic mice. The fusion protein was previously found to constitutively activate FLT3 signaling and transform Ba/F3 cells. Expression of the fusion protein in the transgenic mice was found in all tissues assayed including spleen, bone marrow (BM), thymus and liver. These mice developed splenomegaly and had a high incidence of MPD with extramedullary hematopoiesis in the liver and lymph nodes. Spleens also had increased dendritic and natural killer cell populations. In vitro analysis of the hematopoietic progenitor cells derived from Tel-FLT3 transgenic mice showed a significant increase in the number of CFU-GM in the BM, and CFU-GM, BFU-E and CFU-GEMM in the spleen. BM also showed significant increases of in vivo CFU-S colonies. Thus, transgenic mice expressing constitutively activated Tel-FLT3 develop MPD with a long latency and also result in the expansion of the hematopoietic stem/progenitor cells.
authors.affiliation: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
authors.forename: B R
authors.initials: BR
authors.lastname: Baldwin
authors.forename: L
authors.initials: L
authors.lastname: Li
authors.forename: K-F
authors.initials: KF
authors.lastname: Tse
authors.forename: S
authors.initials: S
authors.lastname: Small
authors.forename: M
authors.initials: M
authors.lastname: Collector
authors.forename: K A
authors.initials: KA
authors.lastname: Whartenby
authors.forename: S J
authors.initials: SJ
authors.lastname: Sharkis
authors.forename: F
authors.initials: F
authors.lastname: Racke
authors.forename: D
authors.initials: D
authors.lastname: Huso
authors.forename: D
authors.initials: D
authors.lastname: Small
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000473:pathology; D004789:Enzyme Activation; D006801:Humans; D008099:Liver / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D009196:Myeloproliferative Disorders / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D013154:Spleen / Q000473:pathology; D013950:Thymus Gland / Q000473:pathology; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
chemical_list: D011993:Recombinant Fusion Proteins; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3